Blood work and increased lipase on retatrutide

The triglyceride effect is positive. Lipase breaks down fat, so the rise could simply reflect your body shifting into a new metabolic state and mobilizing stored fat. An AI note added that retatrutide, as a triple agonist, influences lipase through effects on lipoprotein lipase in fat metabolism and possibly pancreatic lipase levels, lowering ANGPTL3/8 inhibitors and thereby speeding triglyceride clearance.

Thirteen pounds in the first month is mostly water from glycogen plus other shifts and isn't unusual. It's still a solid percentage of body weight. I'm at week 17 averaging about 1 % per week and aiming for 1–1.2 % to stay aggressive yet keep stress reasonable. Sources I read before starting said sustained loss above 1.5 % often leads to problems. I sometimes overshoot in a single week, then adjust and continue. One recent stretch I dropped 4 lb in six days and responded by lowering the dose and eating more freely.

The glycogen and water explanation makes sense on its own, but 13 lb in four weeks together with a fourfold lipase increase isn't something I'd treat as ordinary early loss. That combination looks like a signal worth paying attention to.

Multiple sources I checked this morning agree that asymptomatic lipase rises below 3× the upper limit are treated as a non-issue. Some even advise against routine lipase testing to avoid unnecessary worry. Changes are considered mainly when symptoms develop. I lost 11 lb my first month on tirzepatide and 13 lb my first month on reta, with no pancreatic symptoms; recent labs showed amylase 60 U/L and lipase 53 U/L. Those were my first such tests, so earlier values might have been higher but I have no way to know. Labs aren't viewed as the leading indicator for pancreatitis; they're mainly used when symptoms already suggest a problem. The tests were inexpensive so I wanted the numbers anyway. Do you have sources that say otherwise? I haven't found any besides your comments. Gemini summarized it in one screenshot.

The <3× ULN cutoff comes from pancreatitis diagnostic criteria used by groups like ACG and AGA, where ≥3× ULN plus symptoms helps confirm diagnosis. The same threshold explains why higher asymptomatic elevations aren't automatically ignored. GLP-1 drugs do raise lipase, but trial data usually show modest increases rather than a jump exceeding 4× ULN inside a month. That moves it out of the mild routine category. I'm not claiming this is pancreatitis, yet >3× ULN is typically the point where clinicians at least reassess, especially alongside fast weight loss. To be clear, this isn't about your own labs; the original poster's case is different with the >4× level plus rapid loss, so the caution level differs. Even the screenshot you posted says to stop or adjust once lipase passes 3× ULN.